Instadose Pharma Corp and the Future of Medicinal Cannabis

·4 min read

Instadose Pharma Corp speaks to the potential impact of the growing global market for Medicinal Cannabis and the benefits for the developing world.

BURLINGTON, ON, Oct. 28, 2021 /CNW/ - Instadose Pharma Corp. ("Instadose Canada", "Instadose" or the "Company"), a global wholesale cannabinoid company, is very happy to announce that they will be speaking at Future Cannabis Strategies Europe in London, UK, January 2022. The Company will be focusing on the topic of the development and evolution of the global wholesale Cannabis market and the potential impact and benefits that it may have on the developing world.

Instadose Pharma Corporation logo (CNW Group/Instadose Pharma Corporation)
Instadose Pharma Corporation logo (CNW Group/Instadose Pharma Corporation)

The hope is that these countries will benefit from the development of a global market for Medicinal Cannabis

"The commoditization of Cannabis will have a huge impact on countries where it can be grown outdoors, particularly in the developing world. The hope is that these counties will benefit from the development of a global market for Medicinal Cannabis. Food and water security, as well as, the environment and climate change, are global issues and Medicinal Cannabis could be central to the story as a green renewable resource." said Chairman Grant F. Sanders.

Instadose Pharma Corp participated in a similar virtual conference held by Future Cannabis Strategies North America August 18, 2021 where they spoke on the topic "Evergreen Everlasting" which can be viewed here www.instadosepharma.com/news-media/ever-green-and-ever-lasting

About Instadose Pharma Corp

Instadose is seeking to create a large commercial outdoor growing, cultivation, production and global distribution platform for Medicinal Cannabis and Cannabinoid Oil (the "Global Distribution Platform"). Instadose endeavors to utilize the Global Distribution Platform to open the commercial gateway to a new wholesale marketplace capable of providing pharmaceutical industry companies with large, sustainable, consistent, diverse, and low–cost supplies of high–quality medicinal cannabis and cannabinoid oil for use in bulk as an active pharmaceutical ingredient.

Instadose's Global Distribution Platform spans five (5) world continents to date, including Africa, Europe, Asia, South America, and North America. Within each continent, Instadose is establishing operational subsidiaries and joint venture partnerships to secure access to government-issued licenses and permits in countries including The Democratic Republic of the Congo, the Republic of North Macedonia, the Portuguese Republic, the Republic of India, Colombia, Mexico, and Canada, each seeking to increase their level of participation within the global Medicinal Cannabis industry.

Instadose Pharma's relationships with international partners are based on sustainable, long-term agreements that were initially designed to give back to people and protect the natural environment. Instadose Pharma's projects aim to increase the quality of life, provide jobs, fresh water, education, food security and capital.

Forward Looking Statement

This press release contains forward-looking statements and forward-looking information (collectively "forward-looking information") within the meaning of applicable securities laws relating to the Company's plans and other aspects of our anticipated future opportunities. Forward-looking information typically uses words such as "anticipate", "believe", "continue", "trend", "sustain", "project", "expect", "forecast", "budget", "goal", "guidance", "plan", "objective", "strategy", "target", "intend", "estimate", "potential", or similar words suggesting future outcomes, statements that actions, events or conditions "may", "would", "could" or "will" be taken or occur in the future, including statements about our plans, focus, objectives, priorities and position. In particular, and without limiting the generality of the foregoing, this press release contains forward-looking information with respect to our upcoming shipments of Medical Cannabis. The forward-looking information is based on certain key expectations and assumptions made by our Board and Management. Although we believe that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature they involve inherent risks and uncertainties. Our actual results, performance or achievement could differ materially from those expressed in, or implied by, the forward-looking information and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking information will transpire or occur, or if any of them do so, what benefits that we will derive therefrom. Management has included the above summary of assumptions and risks related to forward-looking information provided in this press release in order to provide security holders with a more complete perspective on our future operations and such information may not be appropriate for other purposes. Readers are cautioned that the foregoing lists of factors are not exhaustive. These forward-looking statements are made as of the date of this press release and we disclaim any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE Instadose Pharma Corporation

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2021/28/c0195.html

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting